

Integrated Testing Strategies for Developmental Neurotoxicity (DNT)

Mamta Behl, Ph.D., DABT Toxicology Branch National Institute of Environmental Health Sciences

NTP Board of Scientific Counselors Meeting December 7-8, 2017





- Background: What is DNT & why do we care?
- Evolution of DNT assessment at the NTP
- Recent Progress
- Where to from here?



- Adverse change in structure or function of nervous system following chemical exposure during prenatal/gestational period
- Approx. 400,000-600,000 children born in the United States every year have neurodevelopmental disorders
- · DNT causes brain damage often untreatable & frequently permanent





- Studying the nervous system is complex!
- Strategies to evaluate DNT are under developed
- In vivo DNT Guideline studies: primary method of evaluation
 - Require a trigger- apriori concern (structural relevance, anticipated use), or findings from a acute/ subchronic study
 - Time & resource intensive
- Compounds with unknown DNT potential remain untested
 - Existing triggers not adequate → require better triggers
 - Guideline studies alone could not keep pace with untested compounds



- Up to 2009: No method to evaluate compounds with potential for DNT on a routine basis
 - Case-by-case; mainly animal studies; mostly acute
 - 1 DNT Guideline study completed until 2009
- Increase in "class nominations"
 - e.g. flame retardants, BPA analogs, PFAS, PAHs, herbals
 - Approx 20-50 compounds/class
- Needed efficient approach to identify & characterize compounds with DNT potential
 - Global issue



- Screen for compounds with potential for DNT
 - Rapid strategies; time & resource honored
 - Prioritize compounds for further testing
 - Complement & refine current DNT Guideline studies based on triggers
- Improve in vivo DNT testing
 - Increase automation/ objective measurements in Guideline studies
 - Integrate with routine developmental assessment v/s stand-alone
 - First study completed in 2017 → data QA → Report

Stay tuned for updates on in vivo DNT testing

Develop a Comprehensive DNT Screening Strategy



Raymond Tice

Assay identified to evaluate DNT



Aschner et al., 2017 & Mundy

Related Assays: General Tox, DT, NT, Neurobehavior



COVERAGE: Rat + Mice + Human + zebrafish + planaria + c.elegans

NTP Created an initial battery to integrate assays





- Which of these assays are critical for a battery?
 - Evaluation of individual assay & in combination
 - Missing areas
- How can the data be integrated across assays?
- How might this information be used in regulatory decisionmaking?
 - Limited access for free and open discussion and to protect researchers unpublished data



NTPs Data Integration Approach



NTPs Proposed Approach for Data Analysis

- Several different ways to analyze data
- For battery, need a unified approach
- After considering different approaches, selected a BMC
 - Used in risk assessment









NTP Analysis Approach





Integration of Data Visualization



NTP Created a Website for Data Visualization



Expected to be made public following primary publications



۹.

Confidentiality statement

National Taxicology Program

Motivation mode analysis to involve participants including information on the RNP restricted access methods or writes the documents that take place during the analysis are confidential and may not be document on at document with anyone who trans and participand in the meeting, anxiet an authorized by D. Manual bell, RNP motivational conductors:

Background: What led to this workshop?

The patients of investministry in addites of children Manning equasions to environmental charakata messare shiph guida priving dui ta sumanni sha messare shiph punch priving dui ta sumanni sha personali sha personali sha personali sha personali sha punch priving dui ta sumanni sha personali sha personal

This asofted pulsing together assorts from matteria, inclusing and the guarancestic plantaux and matching the same of heating segmets that includes high and medican through and a flaunce and all matching and matching and and all flat together assorts and the heating with the same interest and the COULE 1014 and the same of the same and and and all all same and the together assorts and the same interest and the same and the same



Jui-Hua Hsieh

Andy Shapiro

- · How do compounds/ classes look within an assay?
 - Does one compound within a class look different from the others?
- How do compounds/ classes look across assays?
 - Are there assays/ combinations that are informing us about potential targets within the nervous system
- How do assays in the battery compare with each other?
 - Concordance/uniqueness
- How do positive and negative controls perform?
- How do test replicates perform?



Chemical/Class Results within an Assay

Benchmark concentration (BMC) summary by lab @





Comparing across assays





Some interesting patterns that emerged..



- Total 66 out of 80 compounds active in at least one assay
- Different models & endpoints capture different actives
- Zebrafish development covered largest space
- If a compound is active in more than one assay, may inform about patterns
- Negative controls as expected

Take Home: Different domains contributed something unique NEED FOR A BATTERY APPROACH



Highlights of Workshop Discussion





- Experimental Design Considerations
 - Dose ranges, time-points, gender, life-stage, experimental conditions
- Biological Coverage: what are we missing?
 - 3-D models, life stages, BBB, glia, other critical processes
 - Integration with other systems toxicity
- Exposure & Metabolism
 - Physico chem properties, barriers & partitioning, internal conc.
- Data analysis & Modeling
 - Challenges with statistical models ; relevance to biology
- Regulatory Perspective: Complement, Replace, Develop



- Workshop: initial effort on integration using battery approach
 - Publications & releasing website to public
- Continued global discussion on utility of approach
- Continued discussions on data analysis strategies
- External scientific panel for evaluation of battery
- Continue to refine the battery
 - Solicit assays in missing areas identified
- Implement as routine screening at the NTP
 - Feed into in vivo testing



The NTP Workshop Team



Mamta Behl Organizer & Coordinator



Kristen Ryan Co- Coordinator & Organizing Committee



Jui-Hua Hsieh Data Analyst & Application Development



Andy Shapiro Application Lead, Database Lead, & System Administrator



Fred Parham Data Analyst

Paul M. Foster Organizing Committee



Elizabeth A. Maull Co-organizer





Raymond R. Tice Co-organizer



Nigel Walker Organizing Committee



Richard S. Paules Co-Organizer



Key Contributors for Screening Efforts

- Ainhoa Alzualde: Biobide
- Julie Andersen: Buck Institute
- Peter Ash: Boston University
- · Francis Bailey: Health Canada
- Stan Barone: U.S.EPA
- Linda Birnbaum: NIEHS/NTP
- John Bucher: NIEHS/NTP
- Bradley Collins: NIEHS/NTP
- Eva-Maria Collins: UC San Diego
- Kevin Crofton: U.S. EPA
- Katharina Dach: UC Davis
- Eduardo Gonzalez: UC Davis
- Danielle Hagstrom: UC San Diego
- Susanne Hougaard Bennekou: Danish EPA/EFSA
- Pamela Lein: UC Davis
- Elizabeth Mendez: U.S. EPA
- Rafael Miñana Prieto: ZeClinics
- Arantza Muriana: Biobide
- Johanna Nyffeler: University of Konstanz
- Stephanie Padilla: U.S. EPA
- Ying Pei: Xcell Science Inc.

- Mahendra Rao: Xcell Science Inc.
- Elisa Reaves U.S.EPA
- Magdalini Sachana: OECD
- · Timothy Shafer: U.S. EPA
- Nisha Sipes: NIEHS/NTP
- Oksana Sirenko: Molecular Devices
- Robert Tanguay: Oregon State University
- · Javier Terriente: ZeClinics
- · Lisa Truong: Oregon State University
- Molly Vallant: NIEHS/NTP
- Tanja Waldmann: University of Konstanz
- · Benjamin Wolozin: Boston University
- · Georgia Woods: Buck Institute

National & International Representation from Academia, Government, Industry, and Regulatory community